LONDON (Alliance News) - ReNeuron Group PLC Monday said it has received a notice of allowance from the US Patent and Trademark Office for a key patent application covering its cell cryopreservation technology.
The stem cell therapy development company said it has already been issued equivalent patents in Europe, Japan, and Australia.
"The US Notice of Allowance for our cell cryopreservation technology is an important further addition to ReNeuron's extensive patent estate. We have invested heavily in patents over the years, an investment that we believe will provide significant returns for the company as our technologies and therapeutic candidates approach commercialisation," said Chief Executive Officer Olav Hellebø in a statement.
Shares in ReNeuron were trading flat at 2.88 pence Friday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)